Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy

Annals of Nuclear Medicine

Volumn 27, Issue 8, 2013, Pages 748-755

  Yoon, Hai Jeon ^a,d   Paeng, Jin Chul ^a   Kwak, Cheol ^a   Park, Yong Hyun ^a   Kim, Tae Min ^a   Lee, Se Hoon ^a   Chung, June Key ^a   Edmund Kim, E ^b,c   Lee, Dong Soo ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Ewha Womans University School of Medicine   (South Korea)

Author keywords

Advanced renal cell carcinoma; Metabolic tumor burden; PET CT; Prognosis; Targeted therapy

Indexed keywords

CALCIUM; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; ADVANCED CANCER; ARTICLE; BLEEDING; BONE NECROSIS; CALCIUM BLOOD LEVEL; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; GLYCOLYSIS; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER FAILURE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; SPLEEN METASTASIS; TUMOR LYSIS SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEPHRECTOMY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84886424323     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0742-4     Document Type: Article

References (29)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-36.
2. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119-32.
3. Pirrotta MT, Bernardeschi P, Fiorentini G. Targeted-therapy in advanced renal cell carcinoma. Curr Med Chem. 2011;18:1651-7.
4. Crispen PL, Blute ML. Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma. Curr Urol Rep. 2012;13:38-46.
5. Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185:60-6.
6. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117:2873-82.
7. Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. 2010;106:1266-9.
8. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-71.
9. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-50S.
10. max) evaluated by 18-Fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer. 2010;10:667.
11. Orrell DH. Albumin as an aid to the interpretation of serum calcium. Clin Chim Acta. 1971;35:483-9.
12. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-40.
13. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-63.
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer Version 1. 2013. http://www.nccn.org/professionals/ physician-gls/pdf/kidney.pdf. Accessed 15 May 2013.
15. Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 1977;117:272-5.
16. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071-6.
17. Lara PN Jr, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol. 2009;181:512-6.
18. Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, et al. (18) F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011;117:4779-87.
19. Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009;50:340-7.
20. Chihara D, Oki Y, Onoda H, Taji H, Yamamoto K, Tamaki T, et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol. 2011;93:502-8.
21. Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008;113:1552-8.
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
23. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008;247:189-96.
24. Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579-84.
25. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27:535-41.
26. Gilles R, de Geus-Oei LF, Mulders PF, Oyen WJ. Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma. World J Urol 2011.
27. Arslan N, Tuncel M, Kuzhan O, Alagoz E, Budakoglu B, Ozet A, et al. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med. 2011;25:406-13.
28. Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, et al. Volume-based parameter of [18]F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010;17:2787-94.
29. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, et al. Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer. 2011;104:741-5.